SCHEMBL3960658

SCHEMBL3960658

Cc1cc(S(=O)(=O)O)c(NC(=O)Nc2cccc(Br)c2)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 4/20 0.69
GRIK2 Q13002 2/20 0.69
LMNA P02545 2/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
IDH1 O75874 3/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PTGER3 P43115 1/20 0.45
DDX3X O00571 1/20 0.45
TRPV1 Q8NER1 2/20 0.45
STING1 Q86WV6 1/20 0.45
POLB P06746 1/20 0.44
KCNJ6 P48051 1/20 0.44
KCNJ5 P48544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4218069 0.83 KDR (0.61) GRIK1MEN1MAPTHTTKMT2A
SCHEMBL4175803 0.82 GRIK1 (1.00) GRIK1GRIK2LMNAMEN1MAPT
SCHEMBL3958242 0.81 IDH1 (0.56) GRIK1GRIK2MEN1MAPTKMT2A
SCHEMBL17079603 0.74 DDX3X (0.79) GRIK1GRIK2LMNAMEN1MAPT
SCHEMBL19707566 0.73 GAA (0.65) GRIK1GRIK2LMNAMEN1MAPT
SCHEMBL3961846 0.73 GRIK1 (0.52) GRIK1GRIK2MEN1HTTKMT2A
SCHEMBL7656403 0.70 CXCR2 (0.69) GRIK1GRIK2LMNAMEN1MAPT
SCHEMBL11003357 0.70 POLB (0.60) GRIK1GRIK2MEN1MAPTKMT2A
SCHEMBL30995906 0.70 CNR1 (0.67) GRIK1GRIK2LMNAMEN1MAPT
SCHEMBL29556215 0.70 MEN1 (0.67) GRIK1GRIK2LMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521480-B2 Aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2009-04-21 US claimed
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2006-03-30 US claimed
EP-1565429-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2005-08-24 EP claimed
WO-2004046090-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2004-06-03 WO claimed
US-7521480-B2 Aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2009-04-21 US disclosed
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2006-03-30 US disclosed
EP-1565429-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2005-08-24 EP disclosed
WO-2004046090-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use GABRA5, GRIK5, GRM5 GRIK1 24/4885GRIK2 25/4885LMNA 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.